$12.1m pumped into nerve regeneration co:
This article was originally published in Clinica
Executive Summary
AxoGen, the Alachua Florida-based company commercialising peripheral nerve regeneration technologies, has completed a $12.1m series C round. Participants in the financing included Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures and Springboard Capital II. AxoGen launched its Avance nerve graft in July 2007 and intends to use the proceeds for sales and marketing activities. The product is a human allograft nerve that is minimally processed to preserve the natural 3D structure of the nerve basal lamina and the inherent growth promoters within it.